As of 20 Nov 2026, KymaThera has raised $80M across 1 verified round on record; latest: $80m Series B led by Alta Partners, announced 1 Oct 2026.
A provider of precision medicines for genetically defined diseases
kymathera.comSan Diego, CABiotech
14 sources
The source states the company is San Diego-based but does not specify a country or state.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $80M $100M to date | 2026-10-01 | Alta Partners | No recent discussion |
14 sources [ VERIFIED ] read against 1 of 14 sources The source states the company is San Diego-based but does not specify a country or state.; not on the page it cites, so not applied: date | ||||
KymaThera is targeting PI3Kα-mutant cancers and vascular malformations, areas where the company says treatment options remain limited, with K-1728 designed to spare wild-type PI3Kα and address toxicity and incomplete mutation coverage. The $80 million Series B is intended to take the internally discovered, wholly owned program into the clinic, with Phase 1 dosing expected in the fourth quarter of 2026 and funding expected through initial clinical proof-of-concept.